A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

July 5, 2023 updated by: Ocean Spray Cranberries, Inc.

A Randomized, Double-blinded, Placebo-controlled, Crossover Study, to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

This study aims to determine the effect short-term dosing (7 days) of a placebo beverage, cranberry juice, cranberry juice + lemon balm extract, cranberry juice + tart cherry powder, or cranberry juice + L-theanine or L-theanine beverage on cognitive function and mood in healthy adults (18-45 years). The study will include measures of attention, alertness, performance, and mood/stress.

Study Overview

Status

Completed

Conditions

Detailed Description

1.1 Background information Berries from the Vaccinium genus have been reported to improve some measures of cognitive function in healthy adults. There is evidence that the polyphenols contained in berries and other plant foods may play a role in this regard. Among the plant sources of polyphenols, lemon balm and tart cherry reported to have positive effects on cognitive function in randomized controlled trials (RCTs).

L-theanine is an amino acid present almost exclusively in the tea plant (Camellia sinesis). L-theanine crosses the blood-brain barrier and has been shown to increase serotonin and dopamine production in rats. A recent systematic review of RCTs that evaluated the effect of supplemental L-theanine on stress concluded that L-theanine may assist in the reduction of stress.

Given that plant bioactives may have varying mechanisms to support cognitive health, the aim of this study is as follows:

Aim 1: To determine the effect short-term dosing (7 days) of a placebo beverage, cranberry juice, cranberry juice + lemon balm extract, cranberry juice + tart cherry powder, or cranberry juice + L-theanine or L-theanine beverage on cognitive function and mood in healthy adults (18-45 years). The study will include measures of attention, alertness, performance, and mood/stress.

1.2 Investigational product

Beverage to be tested:

  • 100% cranberry juice (8 oz, Ocean Spray)
  • 100% cranberry juice (8 oz) + lemon balm extract (300 mg)
  • 100% cranberry juice (8 oz) + tart cherry powder (3 g)
  • 100% cranberry juice (8 oz) + L-theanine (200 mg)
  • L-theanine (200 mg) + placebo (matched for color, taste, calories)
  • placebo (matched for color, taste, calories) 1.3 Rationale for conducting the clinical trial There is scientific support for Vaccinium berries to be of benefit to cognitive health. However, this has not be specifically tested in cranberries (Vaccinium macrocarpon). Furthermore, the individual effects of the other ingredients to be tested in this trial have been found to have positive effects on cognitive health but whether there are added effects with cranberry is not known.

    2 OBJECTIVES 2.1 Primary objective To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on attention.

2.2 Primary endpoint variable

  • Change in Accuracy of Attention composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
  • Change in Speed of Attention composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.

2.3 Secondary objectives To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of focus, alertness, and cognition.

To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on mood and stress.

2.4 Secondary endpoint variables

  • Focus: Change in Overall % accuracy scores outcomes from Baseline to each treatment phase (V3-8), assessed using the STROOP task in the COMPASS cognitive assessment tool.
  • Alertness: Change in Alertness scores outcomes from Baseline to each treatment phase (V3-8), assessed using the self-rated Alertness VAS scale in the COMPASS cognitive assessment tool.
  • Cognitive Performance:

    • Change in Accuracy of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
    • Change in Speed of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
  • Mood: Change in Total Mood Disturbance scores from Baseline to each subsequent visit (V3-8), assessed using the Profile of Mood States-Short Questionnaire.
  • Stress: Change in salivary cortisol from Baseline to each treatment phase (V3-8).

2.5 Exploratory objectives Dependent upon the outcome of the Primary and Secondary objectives, additional outcomes from the COMPASS cognitive assessment tool may be analyzed further to assess the impact of the investigational product on various domains of cognition.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60611
        • Atlantia Clinical Trials Ltd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

To be eligible for inclusion, the participant must fulfil all of the following criteria:

  1. Be able to give written informed consent and willing/able to comply with study procedures.
  2. Be between 18 and 45 years, inclusive.
  3. Is in general good health, as determined by the investigator.
  4. Has a BMI between ≥20 - ≤35 kg/m2.
  5. Has had a stable body weight (≤5 % change) over the past 3-months.
  6. Has a Beck Depression Inventory II score ≤20 at screening.
  7. Willing to discontinue consumption of wine and dark red/blue colored fruits and polyphenol-rich fruits (e.g., pomegranate, blueberries, grapes), lemon balm, tart cherry powder, and L-Theanine for the two weeks leading up to the study (from the Screening visit V1 to baseline V2) and during the study.
  8. Willing and able to avoid consumption of any cranberry juice, whole cranberries, and dried cranberries for the two weeks leading up to the study (from the Screening visit V1 to baseline V2) and during the study, excluding the study beverage.
  9. Is willing to provide saliva samples.
  10. Maintain current level of physical activity and dietary habits throughout the study.

Exclusion Criteria:

Participants that meet any of the following criteria will be excluded from the trial:

  1. Has a known or suspected allergy to components of the investigational product (e.g., cranberries, tart cherry, lemon balm, L-theanine).
  2. Uncontrolled blood pressure or untreated hypertension.
  3. Consumes >2 alcoholic beverages per day or >14 per week.
  4. Major chronic illness or health condition that might interfere with the study outcomes at the discretion of the study clinician or principal investigator.
  5. Use of antidepressant, anxiolytic, Central Nervous System stimulant, antipsychotic, antimanic, anti-inflammatory (except for aspirin and non-steroidal anti-inflammatory drugs [NSAIDS]. Multivitamins, vaccines, gender affirming hormones, HIV prevention medications, allergy medications, topical steroids are allowed for inclusion.)
  6. Individuals who smoke or use nicotine patches or gum or e-cigarettes, or marijuana (within the past 6 months).
  7. Individuals who have experienced a stroke or a head injury with concussion, loss of consciousness or seizures.
  8. History or clinical manifestation of any significant neurologic disorder in the opinion of the investigator and/or study clinician.
  9. Any disease, that by the investigator's judgement, could interfere with the intestinal barrier function, including Celiac disease (Lactose intolerance or acid reflux are allowed for inclusion).
  10. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than one month prior to this trial.
  11. Desire and/or plans on changing current diet and/or exercise regime during the participation of this trial.
  12. Individuals who are pregnant or lactating.
  13. Individuals currently of childbearing potential, but not using an effective method of contraception, as determined by the investigator.
  14. History of heavy caffeinated beverage consumption (>400 mg caffeine/day - or 4 cups of coffee per day) within past 2 weeks prior to the Screening Visit (V1), or before their Baseline Visit (V2).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: First Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence.

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product
Experimental: Second Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product
Experimental: Third Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product
Experimental: Fourth Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product
Experimental: Fifth Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product
Experimental: Sixth Product Order: order not stated to protect study blinding
Participants will receive each of the 6 study products sequentially in a cross-over design, consuming one study product for 7 days, followed by a 7 day wash-out period before beginning the next product in the sequence

The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)

The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)

The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)

The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)

L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)

The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.

Other Names:
  • Cranberry Juice + Lemon Balm Extract Product
  • Cranberry Juice + Tart Cherry Juice Product
  • Cranberry Juice + L-theanine Product
  • L-theanine + Placebo Product
  • Placebo Product

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on attention.
Time Frame: 7 days
Change in Accuracy of Attention and Change in Speed of Attention composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of focus.
Time Frame: 7 days
Change in Overall % accuracy scores outcomes from Baseline to each treatment phase (V3-8), assessed using the STROOP task in the COMPASS cognitive assessment tool.
7 days
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of alertness.
Time Frame: 7 days
Change in Alertness scores outcomes from Baseline to each treatment phase (V3-8), assessed using the self-rated Alertness Visual Analogue Scale in the COMPASS cognitive assessment tool.
7 days
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of cognition (accuracy of performance).
Time Frame: 7 days
Change in Accuracy of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
7 days
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on measures of cognition (speed of performance).
Time Frame: 7 days
Change in Speed of Performance composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
7 days
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on mood.
Time Frame: 7 days
Change in Total Mood Disturbance scores from Baseline to each subsequent visit (V3-8), assessed using the Profile of Mood States-Short Questionnaire.
7 days
To evaluate in healthy adults the effect of 7-day consumption of cranberry beverages compared to placebo on stress.
Time Frame: 7 days
Change in salivary cortisol from Baseline to each treatment phase (V3-8).
7 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Proportion of Adverse Events).
Time Frame: 7 days
Proportion of Adverse Events per treatment phase by product causality.
7 days
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Incidence of Adverse Events).
Time Frame: 7 days
Incidence of mild, moderate, and severe Adverse Events per treatment phase by product causality.
7 days
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Incidence of Serious Adverse Events).
Time Frame: 7 days
Incidence of Serious Adverse Events per treatment phase by product causality.
7 days
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Blood Pressure).
Time Frame: 7 days
Change in Blood Pressure from Baseline to each subsequent visit (V3-8).
7 days
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Heart Rate).
Time Frame: 7 days
Change in Heart Rate from Baseline to each subsequent visit (V3-8).
7 days
To evaluate in healthy adults the safety and tolerability of 7-day consumption of cranberry beverages compared to placebo (Body Temperature).
Time Frame: 7 days
Change in Body Temperature from Baseline to each subsequent visit (V3-8).
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alice Eggleston, PA-C, MPH, Atlantia Clinical Trials LTD.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2021

Primary Completion (Actual)

November 1, 2021

Study Completion (Actual)

November 1, 2021

Study Registration Dates

First Submitted

July 14, 2021

First Submitted That Met QC Criteria

August 9, 2021

First Posted (Actual)

August 17, 2021

Study Record Updates

Last Update Posted (Actual)

July 7, 2023

Last Update Submitted That Met QC Criteria

July 5, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • AFCRO-140

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mood

Clinical Trials on Cranberry Juice Product

Subscribe